EP0973513A4 - Compositions et methodes pour traiter les etats associes a un deficit osseux - Google Patents
Compositions et methodes pour traiter les etats associes a un deficit osseuxInfo
- Publication number
- EP0973513A4 EP0973513A4 EP97912787A EP97912787A EP0973513A4 EP 0973513 A4 EP0973513 A4 EP 0973513A4 EP 97912787 A EP97912787 A EP 97912787A EP 97912787 A EP97912787 A EP 97912787A EP 0973513 A4 EP0973513 A4 EP 0973513A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- treating bone
- deficit conditions
- bone deficit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US735881 | 1985-05-16 | ||
US735873 | 1991-07-25 | ||
US73622096A | 1996-10-23 | 1996-10-23 | |
US73631996A | 1996-10-23 | 1996-10-23 | |
US73587096A | 1996-10-23 | 1996-10-23 | |
US73622896A | 1996-10-23 | 1996-10-23 | |
US73587496A | 1996-10-23 | 1996-10-23 | |
US73588196A | 1996-10-23 | 1996-10-23 | |
US73622196A | 1996-10-23 | 1996-10-23 | |
US73631896A | 1996-10-23 | 1996-10-23 | |
US73622296A | 1996-10-23 | 1996-10-23 | |
US73587696A | 1996-10-23 | 1996-10-23 | |
US73587396A | 1996-10-23 | 1996-10-23 | |
US736221 | 1996-10-23 | ||
US736220 | 1996-10-23 | ||
US736319 | 1996-10-23 | ||
US736222 | 1996-10-23 | ||
US736228 | 1996-10-23 | ||
US735870 | 1996-10-23 | ||
US735876 | 1996-10-23 | ||
US735874 | 1996-10-23 | ||
US736318 | 1996-10-23 | ||
PCT/US1997/018864 WO1998017267A1 (fr) | 1996-10-23 | 1997-10-23 | Compositions et methodes pour traiter les etats associes a un deficit osseux |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0973513A1 EP0973513A1 (fr) | 2000-01-26 |
EP0973513A4 true EP0973513A4 (fr) | 2003-03-19 |
Family
ID=27582807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97912787A Withdrawn EP0973513A4 (fr) | 1996-10-23 | 1997-10-23 | Compositions et methodes pour traiter les etats associes a un deficit osseux |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0973513A4 (fr) |
JP (1) | JP2001510450A (fr) |
AU (1) | AU4988997A (fr) |
WO (1) | WO1998017267A1 (fr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008208A (en) | 1995-10-23 | 1999-12-28 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
AU706262B2 (en) * | 1995-10-23 | 1999-06-10 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
US6376476B1 (en) | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
US6369091B1 (en) | 1998-05-22 | 2002-04-09 | Avanir Pharmaceuticals | Benzimidazole analogs as down-regulators of IgE |
US6303645B1 (en) | 1998-05-22 | 2001-10-16 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
US6911462B2 (en) | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
US6919366B2 (en) | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
ATE292465T1 (de) * | 1998-05-22 | 2005-04-15 | Avanir Pharmaceuticals | Benzimidazol-derivate als ige-modulatoren |
US6489344B1 (en) * | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
EP2298311B1 (fr) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6593353B1 (en) | 1999-01-29 | 2003-07-15 | Board Of Trustees Of The University Of Illinois | p53 inhibitors and therapeutic use of the same |
IL145508A0 (en) * | 1999-03-26 | 2002-06-30 | Euro Celtique Sa | Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same |
WO2000078351A1 (fr) * | 1999-06-18 | 2000-12-28 | Mitsubishi Pharma Corporation | Promoteurs de l'osteogenese |
WO2001017562A1 (fr) * | 1999-09-02 | 2001-03-15 | Yamanouchi Pharmaceutical Co., Ltd. | Agents promoteurs de l'osteogenese |
US6759425B2 (en) | 1999-10-21 | 2004-07-06 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
JP5278983B2 (ja) * | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
CN1242993C (zh) | 2000-03-31 | 2006-02-22 | 日本新药株式会社 | 杂环衍生物和药物 |
US7270800B2 (en) | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
PT2264018E (pt) * | 2000-08-24 | 2015-06-03 | Univ Pittsburgh | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer |
PT1368028E (pt) | 2001-03-12 | 2007-11-26 | Avanir Pharmaceuticals | Compostos de benzimidazole para modulação de ige e inibição da proliferação celular |
WO2002085903A2 (fr) | 2001-04-23 | 2002-10-31 | The Trustees Of The University Of Pennsylvania | Inhibiteurs d'agregation de plaque amyloide et agents d'imagerie diagnostique |
US7405235B2 (en) | 2001-05-04 | 2008-07-29 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
US6660737B2 (en) | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
CN1638765A (zh) * | 2001-07-27 | 2005-07-13 | 柯里斯公司 | Hedgehog信号转导途径介质、其相关组合物以及应用 |
US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
US7064139B2 (en) * | 2001-10-29 | 2006-06-20 | Uniroyal Chemical Company, Inc. | Method for treating retroviral infections |
UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
WO2003068228A1 (fr) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Urees aryliques a activite inhibitrice d'angiogenese |
DK1580188T3 (da) | 2002-02-11 | 2012-02-06 | Bayer Healthcare Llc | Forbindelser af arylurea som kinaseinhibitorer |
US7718663B2 (en) | 2002-04-26 | 2010-05-18 | Nippon Shinyaku Co., Ltd. | Quinazoline derivatives and medicaments |
SE0202134D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
US7247741B2 (en) | 2005-01-21 | 2007-07-24 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
EP1525185A1 (fr) * | 2002-07-24 | 2005-04-27 | PTC Therapeutics, Inc. | Composes d'acide acetylamino benzoique et leur utilisation pour la suppression de non-sens et le traitement de maladie |
TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
JP2006513162A (ja) * | 2002-11-01 | 2006-04-20 | パラテック ファーマシューティカルズ インコーポレイテッド | 転写因子調節化合物およびその使用方法 |
EP1636585B2 (fr) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl-urees presentant une activite d'inhibition des kinases |
ME00294B (fr) | 2003-07-23 | 2011-05-10 | Bayer Pharmaceuticals Corp | Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques |
US8236282B2 (en) | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
FR2860431A1 (fr) * | 2003-10-02 | 2005-04-08 | Oreal | Composition capillaire ou de mascara contenant un compose azoique, son utilisation pour stimuler ou induire la pousse des cheveux ou des cils et/ou freiner leur chute |
ITTO20040125A1 (it) * | 2004-03-01 | 2004-06-01 | Rotta Research Lab | Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica |
EP1742637A4 (fr) | 2004-04-23 | 2011-06-08 | Paratek Pharm Innc | Composes de modulation de facteur de transcription et leurs procedes d'utilisation |
MXPA06012333A (es) | 2004-04-30 | 2007-01-17 | Takeda Pharmaceutical | Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13. |
US20100063046A1 (en) * | 2006-05-17 | 2010-03-11 | Whitten Jeffrey P | Tetracyclic imidazole analogs |
JP5186303B2 (ja) * | 2008-07-31 | 2013-04-17 | 東京応化工業株式会社 | レジスト組成物およびレジストパターン形成方法 |
CN103209968B (zh) * | 2010-08-26 | 2015-08-05 | 国立大学法人京都大学 | 多能干细胞心肌细胞分化促进剂 |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
CN102558091B (zh) * | 2011-12-22 | 2014-10-08 | 合肥工业大学 | 一种苯并噻唑类衍生物及其用途 |
KR101996343B1 (ko) * | 2012-01-27 | 2019-07-05 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 전능성 줄기세포의 심근분화 유도방법 |
EP3147280B1 (fr) | 2012-07-18 | 2018-03-07 | University College Dublin, National University of Ireland, Dublin | Composé anti-angiogène |
CN102942515A (zh) * | 2012-10-22 | 2013-02-27 | 暨南大学 | 一种乙烯桥连吲哚化合物及其合成方法和用途 |
EP2966166B1 (fr) | 2013-03-08 | 2019-04-03 | Kyoto University | Promoteur de différenciation d'une cellule souche pluripotente en myocarde, lequel comprend un inhibiteur d'un récepteur d'egf |
WO2015182765A1 (fr) | 2014-05-30 | 2015-12-03 | 国立大学法人京都大学 | Procédé d'induction de la différenciation myocardique des cellules souches pluripotentes à l'aide d'un composé de faible poids moléculaire |
CN106188003B (zh) * | 2016-07-22 | 2019-01-22 | 清华大学深圳研究生院 | 基于喹啉骨架的Cu2+和Fe3+双靶点荧光探针及其制备方法和应用 |
CN112010846A (zh) * | 2019-05-30 | 2020-12-01 | 四川大学华西医院 | 一种吡啶衍生物及其制备方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2058564A (en) * | 1979-09-07 | 1981-04-15 | Horton J E | Pharmaceutical compositions comprising anti-osteoporotic agents |
US4889851A (en) * | 1986-11-21 | 1989-12-26 | Fujisawa Pharmaceutical Co, Ltd. | Benzothiadiazine compounds, and pharmaceutical composition comprising the same |
EP0740936A2 (fr) * | 1995-05-05 | 1996-11-06 | Adir Et Compagnie | Utilisation des dérivés du benzopyrane pour l' obtention de compositions pharmaceutiques destinées au traitement des pathologies liées a l'énchangeur Cl-/HCO3-,Na+ indépendant |
WO1997015308A1 (fr) * | 1995-10-23 | 1997-05-01 | Zymogenetics, Inc. | Compositions et procedes pour le traitement des deficits osseux |
EP0783888A1 (fr) * | 1995-12-26 | 1997-07-16 | Sankyo Company Limited | Utilisation de la troglitazone et de thiazolidinediones apparentées dans la fabrication d'un médicament destiné au traitement et la prévention de l'ostéoporose |
WO1997048694A1 (fr) * | 1996-06-20 | 1997-12-24 | Board Of Regents, The University Of Texas System | Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5441964A (en) * | 1993-10-15 | 1995-08-15 | Eli Lilly And Company | Methods for inhibiting bone loss using substituted benzothiophene |
US5523309A (en) * | 1995-03-10 | 1996-06-04 | Eli Lilly And Company | Benzofuran pharmaceutical compounds |
US5622974A (en) * | 1995-03-10 | 1997-04-22 | Eli Lilly And Company | α-substituted-3-benzyl-benzofurans |
-
1997
- 1997-10-23 EP EP97912787A patent/EP0973513A4/fr not_active Withdrawn
- 1997-10-23 WO PCT/US1997/018864 patent/WO1998017267A1/fr not_active Application Discontinuation
- 1997-10-23 JP JP51952998A patent/JP2001510450A/ja active Pending
- 1997-10-23 AU AU49889/97A patent/AU4988997A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2058564A (en) * | 1979-09-07 | 1981-04-15 | Horton J E | Pharmaceutical compositions comprising anti-osteoporotic agents |
US4889851A (en) * | 1986-11-21 | 1989-12-26 | Fujisawa Pharmaceutical Co, Ltd. | Benzothiadiazine compounds, and pharmaceutical composition comprising the same |
EP0740936A2 (fr) * | 1995-05-05 | 1996-11-06 | Adir Et Compagnie | Utilisation des dérivés du benzopyrane pour l' obtention de compositions pharmaceutiques destinées au traitement des pathologies liées a l'énchangeur Cl-/HCO3-,Na+ indépendant |
WO1997015308A1 (fr) * | 1995-10-23 | 1997-05-01 | Zymogenetics, Inc. | Compositions et procedes pour le traitement des deficits osseux |
EP0783888A1 (fr) * | 1995-12-26 | 1997-07-16 | Sankyo Company Limited | Utilisation de la troglitazone et de thiazolidinediones apparentées dans la fabrication d'un médicament destiné au traitement et la prévention de l'ostéoporose |
WO1997048694A1 (fr) * | 1996-06-20 | 1997-12-24 | Board Of Regents, The University Of Texas System | Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Week 198314, Derwent World Patents Index; AN 1983-33820k, XP002228668 * |
RD-227016 A (10-03-1983) * |
See also references of WO9817267A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998017267A1 (fr) | 1998-04-30 |
EP0973513A1 (fr) | 2000-01-26 |
AU4988997A (en) | 1998-05-15 |
JP2001510450A (ja) | 2001-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0973513A4 (fr) | Compositions et methodes pour traiter les etats associes a un deficit osseux | |
EP0866710A4 (fr) | Compositions et procedes pour le traitement des deficits osseux | |
IL138430A0 (en) | Methods and compositions for treating and preventing mucositis | |
IL134205A0 (en) | Phototherapy based method for treating pathogens and compositions for effecting same | |
IL129555A0 (en) | Methods and compositions for stimulating neurite growth | |
IL115405A0 (en) | Compositions and methods for treating mast-cell mediated conditions | |
GR3036364T3 (en) | Compositions and methods for treating or preventing inflammatory diseases | |
ZA9710248B (en) | Methods and compositions for stimulating neurite growth. | |
ZA9710258B (en) | Methods and compositions for stimulating neurite growth. | |
HUP9900960A3 (en) | Disinfecting compositions and method for disinfecting surfaces | |
EP0961613A4 (fr) | Methodes et compositions pour le traitement des troubles de la resorption osseuse, y compris l'osteoporose | |
HK1023371A1 (en) | Compositions and methods for treating viral infections | |
EP0946158A4 (fr) | Compositions et procede de bronzage de la peau | |
AU9214398A (en) | Compositions and methods for treating water | |
EP1088333A4 (fr) | Compositions et procedes inhibant la resorption osseuse | |
EP1109548A4 (fr) | Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses | |
ZA981600B (en) | Methods and compositions for treating stickies | |
GB9621570D0 (en) | Formulations and methods for inhibiting bone loss | |
IL115021A0 (en) | Methods for inhibiting bone prosthesis degeneration | |
GB9624501D0 (en) | Insecticial compositions and method | |
IL111554A0 (en) | Methods and compositions for hair treatment | |
AU5594398A (en) | Methods and compositions for preventing and treating bone loss | |
EP0835092A4 (fr) | Composition et traitement pour la lutte contre la calvitie | |
AU5791698A (en) | Methods and compositions for preventing and treating bone loss | |
EP1089750A4 (fr) | Compositions et procedes permettant d'inhiber la resorption d'un os |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990512 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM Owner name: OSTEOSCREEN, INC. Owner name: ZYMOGENETICS, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20030205 |
|
17Q | First examination report despatched |
Effective date: 20040909 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050120 |